Tirzepatide is at the moment utilized as a 2nd-line diabetic issues medication akin to GLP-one drugs, including semaglutide, and it is administered when weekly via subcutaneous injection with incremental dosage changes. Tirzepatide isn't accepted to the treatment of type one diabetic issues